Literature DB >> 15739033

Role of chronic health disorders in perimenopausal fractures.

Jukka Huopio1, Risto Honkanen, Jukka Jurvelin, Seppo Saarikoski, Esko Alhava, Heikki Kröger.   

Abstract

Only a few studies have examined the risk of individual chronic health disorders on perimenopausal (i.e., around menopause) fractures in a single study. We evaluated the effect of chronic illnesses on fracture rate in a prospective cohort study of 3,078 women. These women were a stratified sample from the population base of 14,220 women aged 47-56 years and residing in the province of Kuopio in eastern Finland in 1989. Data on physician-diagnosed chronic diseases were collected by a baseline questionnaire in 1989. For certain diseases, questionnaire information of self-reported chronic disorders were compared with drug reimbursement data provided by the Social Insurance Institution of Finland. Axial bone mineral density (BMD) measurements from the femoral neck and lumbar spine were performed in 1989-91. Two hundred sixty-five (265) women experienced at least one fracture during the follow-up period of 3.6 years (SD+/-0.78). The first fracture during the follow-up period was taken to be the end-point event. The risk of follow-up fracture for an individual health disorder was estimated with the Cox's proportional hazards model. Several chronic health disorders increased the fracture risk in perimenopausal women. However, hypertension was a statistically significant (p=0.018) risk factor for fracture (adjusted hazard ratio [HR], 1.4; 95% confidence interval [CI], 1.1-1.9), especially in overweight and obese (body mass index > or =28) women (HR, 2.0; 95% CI, 1.4-3.0). In addition, coronary heart disease (adjusted HR, 1.76; 95% CI, 1.13-2.76), hyperthyroidism (adjusted HR, 1.7; 95% CI, 1.0-2.9), epilepsy (adjusted HR, 2.0; 95% CI, 1.1-3.6), alcoholism (adjusted HR, 3.5; 95% CI, 1.3-9.5) and chronic hepatic disease (adjusted HR, 5.2; 95% CI, 1.7-16.4) predicted fracture. BMD was either normal or even elevated in disease groups. However, women with a fracture during the follow-up usually had decreased bone density, although the difference was statistically significant only in women with hypertension and hyperthyroidism. We conclude that hypertension, coronary heart disease, alcoholism, epilepsy and hyperthyroidism can markedly increase the risk of fracture in perimenopausal women and should be taken into account when assessing the risk of future fracture in an individual patient. Furthermore, in contrast to previous data, obesity alone does not increase the risk of perimenopausal fracture, but in association with hypertension the risk seems to be markedly elevated.

Entities:  

Mesh:

Year:  2005        PMID: 15739033     DOI: 10.1007/s00198-005-1851-2

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  32 in total

1.  Hormone replacement therapy and risk of falling in early postmenopausal women - a population-based study.

Authors:  K M Randell; R J Honkanen; M H Komulainen; M T Tuppurainen; H Kröger; S Saarikoski
Journal:  Clin Endocrinol (Oxf)       Date:  2001-06       Impact factor: 3.478

2.  Postprandial systolic blood pressure responses of older people in residential care: association with risk of falling.

Authors:  David G Le Couteur; Alex A Fisher; Michael W Davis; Allan J McLean
Journal:  Gerontology       Date:  2003 Jul-Aug       Impact factor: 5.140

3.  Risk factors for perimenopausal fractures: a prospective study.

Authors:  J Huopio; H Kröger; R Honkanen; S Saarikoski; E Alhava
Journal:  Osteoporos Int       Date:  2000       Impact factor: 4.507

4.  Cardiovascular diseases and risk factors in a population-based study in The Netherlands: agreement between questionnaire information and medical records.

Authors:  O H Klungel; A de Boer; A H Paes; J C Seidell; A Bakker
Journal:  Neth J Med       Date:  1999-10       Impact factor: 1.422

5.  Fractures between the ages of 20 and 50 years increase women's risk of subsequent fractures.

Authors:  Fiona Wu; Barbara Mason; Anne Horne; Ruth Ames; Judith Clearwater; Michael Liu; Margaret C Evans; Gregory D Gamble; Ian R Reid
Journal:  Arch Intern Med       Date:  2002-01-14

6.  Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women.

Authors:  K K Nicodemus; A R Folsom
Journal:  Diabetes Care       Date:  2001-07       Impact factor: 19.112

7.  Validity of self-reports of fractures in perimenopausal women.

Authors:  K Honkanen; R Honkanen; L Heikkinen; H Kröger; S Saarikoski
Journal:  Am J Epidemiol       Date:  1999-09-01       Impact factor: 4.897

Review 8.  Calcium and osteoporosis.

Authors:  B E Nordin
Journal:  Nutrition       Date:  1997 Jul-Aug       Impact factor: 4.008

9.  Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.

Authors:  Jane A Cauley; John Robbins; Zhao Chen; Steven R Cummings; Rebecca D Jackson; Andrea Z LaCroix; Meryl LeBoff; Cora E Lewis; Joan McGowan; Joan Neuner; Mary Pettinger; Marcia L Stefanick; Jean Wactawski-Wende; Nelson B Watts
Journal:  JAMA       Date:  2003-10-01       Impact factor: 56.272

10.  Risk of extremity fractures in adult outpatients with epilepsy.

Authors:  Hakan B I Persson; K A Alberts; B Y Farahmand; T Tomson
Journal:  Epilepsia       Date:  2002-07       Impact factor: 5.864

View more
  2 in total

1.  Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study.

Authors:  J Blouin; A Dragomir; M Fredette; L-G Ste-Marie; J C Fernandes; S Perreault
Journal:  Osteoporos Int       Date:  2008-12-24       Impact factor: 4.507

2.  Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and The Netherlands.

Authors:  F de Vries; P C Souverein; C Cooper; H G M Leufkens; T P van Staa
Journal:  Calcif Tissue Int       Date:  2007-02-02       Impact factor: 4.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.